{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:01:55Z","timestamp":1786978915173,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00823-7","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:21:10Z","timestamp":1786976470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility"],"prefix":"10.1007","author":[{"given":"Lucas Maciel de Almeida","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Rian","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Belo Gamon","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre de Assis","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Felipe","family":"Dutra J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Costa","family":"de Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiggi Kevin Virgino","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Roberth","family":"Delmiro Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Esteves","family":"Dante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/AH.98623","volume":"28","author":"S Surma","year":"2024","unstructured":"Surma S, Oparil S. Zilebesiran - the first siRNA-based drug in hypertensiology: why is it needed, and will it change the treatment approach of hypertension? Arter Hypertens. 2024;28:1\u201311. https:\/\/doi.org\/10.5603\/AH.98623.","journal-title":"Arter Hypertens"},{"key":"823_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92446","volume":"17","author":"M Raza","year":"2025","unstructured":"Raza M, Riaz CZ, Chaudhry ER, Jannat M, Basit AR, Qureshi AJ, et al. Efficacy and safety of zilebesiran for the management of hypertension: an updated systematic review and meta-analysis of randomised controlled trials. Cureus. 2025;17:e92446. https:\/\/doi.org\/10.7759\/cureus.92446.","journal-title":"Cureus"},{"key":"823_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000962","author":"D Maheta","year":"2025","unstructured":"Maheta D, Shah F, Biba V, Ngardig NN, Agrawal SP, Rajput J, et al. Zilebesiran: a novel RNA interference therapeutic for hypertension. Cardiol Rev. 2025. https:\/\/doi.org\/10.1097\/CRD.0000000000000962.","journal-title":"Cardiol Rev"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331:740\u20139. https:\/\/doi.org\/10.1001\/jama.2024.0728.","journal-title":"JAMA"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","volume":"334","author":"AS Desai","year":"2025","unstructured":"Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, et al. Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA. 2025;334:46\u201355. https:\/\/doi.org\/10.1001\/jama.2025.6681.","journal-title":"JAMA"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.124.22878","volume":"81","author":"D Ye","year":"2024","unstructured":"Ye D, Cruz-L\u00f3pez EO, van Veghel R, Garrelds IM, Kasper A, Wassarman K, et al. Counteracting angiotensinogen small-interfering RNA-mediated antihypertensive effects with REVERSIR. Hypertension. 2024;81:1491\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22878.","journal-title":"Hypertension"},{"key":"823_CR8","unstructured":"Pagidipati N. KARDIA-3: zilebesiran as add-on therapy in adults with hypertension and established cardiovascular disease or at high cardiovascular risk. In: Professional Heart Daily. 2025. https:\/\/professional.heart.org\/en\/-\/media\/PHD-Files\/Meetings\/Other-Cardiovascular-and-Related-Conferences\/ESC\/2025\/KARDIA3-FINAL.pdf. Accessed 27 Mar 2026"},{"key":"823_CR9","unstructured":"ClinicalTrials.gov. Zilebesiran in patients with hypertension at high cardiovascular risk (ZENITH). https:\/\/clinicaltrials.gov\/study\/NCT07181109. Accessed 27 Mar 2026"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-1-4160-3163-5.50013-0","volume-title":"Nephrology and fluid\/electrolyte physiology: neonatology questions and controversies","author":"A Natarajan","year":"2008","unstructured":"Natarajan A, Jose PA. Renal modulation: the renin-angiotensin-aldosterone system (RAAS). In: Oh W, Guignard JP, Baumgart S, editors. Nephrology and fluid\/electrolyte physiology: neonatology questions and controversies. Philadelphia: Saunders\/Elsevier; 2008. p. 107\u201327. https:\/\/doi.org\/10.1016\/B978-1-4160-3163-5.50013-0."},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00424-024-02908-1","volume":"476","author":"H Triebel","year":"2024","unstructured":"Triebel H, Castrop H. The renin angiotensin aldosterone system. Pflugers Arch. 2024;476:705\u201313. https:\/\/doi.org\/10.1007\/s00424-024-02908-1.","journal-title":"Pflugers Arch"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2022.10.012","volume":"81","author":"KE Watson","year":"2023","unstructured":"Watson KE, Dhaliwal K, Robertshaw S, Verdin N, Benterud E, Lamont N, et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023;81:564\u201374. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.012.","journal-title":"Am J Kidney Dis"},{"key":"823_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020343","volume":"13","author":"M Truong","year":"2024","unstructured":"Truong M, Tesfaye W, Sud K, Van C, Seth S, Croker N, et al. Drug-related problems and sick day management considerations for medications that contribute to the risk of acute kidney injury. J Clin Med. 2024;13:343. https:\/\/doi.org\/10.3390\/jcm13020343.","journal-title":"J Clin Med"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14712598.2024.2425343","volume":"24","author":"SA Doggrell","year":"2024","unstructured":"Doggrell SA. Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension? Expert Opin Biol Ther. 2024;24:1329\u201334. https:\/\/doi.org\/10.1080\/14712598.2024.2425343.","journal-title":"Expert Opin Biol Ther"},{"key":"823_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2026.01.013","author":"R Nahlawi","year":"2026","unstructured":"Nahlawi R, Majeed Z, Motairek I, Martyn T, Alvarez P, Jaber WA, et al. Renin-angiotensin-aldosterone system (RAAS) antagonists in the perioperative setting: an updated review. Am J Med. 2026. https:\/\/doi.org\/10.1016\/j.amjmed.2026.01.013.","journal-title":"Am J Med"},{"key":"823_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207365","volume":"14","author":"S Dudzicz-Gojowy","year":"2025","unstructured":"Dudzicz-Gojowy S, Adamczak M. Zilebesiran\u2014small interfering RNAs as prospective new drug in the treatment of hypertension. J Clin Med. 2025;14:7365. https:\/\/doi.org\/10.3390\/jcm14207365.","journal-title":"J Clin Med"},{"key":"823_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110717","volume":"26","author":"PA Morosan","year":"2025","unstructured":"Morosan PA, Bobu AM, Carauleanu A, Popa R, Costea CF, Filip C, et al. Zilebesiran as an innovative siRNA-based therapeutic approach for hypertension: emerging perspectives in cardiovascular medicine. Int J Mol Sci. 2025;26:10717. https:\/\/doi.org\/10.3390\/ijms262110717.","journal-title":"Int J Mol Sci"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/HYP.0000000000000047","volume":"68","author":"F Elijovich","year":"2016","unstructured":"Elijovich F, Weinberger MH, Anderson CAM, Appel LJ, Bursztyn M, Cook NR, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68:e7\u201346. https:\/\/doi.org\/10.1161\/HYP.0000000000000047.","journal-title":"Hypertension"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","volume":"380","author":"R Bellomo","year":"2012","unstructured":"Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380:756\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(11)61454-2.","journal-title":"Lancet"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","volume":"394","author":"C Ronco","year":"2019","unstructured":"Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394:1949\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(19)32563-2.","journal-title":"Lancet"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41581-021-00418-2","volume":"17","author":"JR Prowle","year":"2021","unstructured":"Prowle JR, Forni LG, Bell M, Chew MS, Edwards M, Grams ME, et al. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol. 2021;17:605\u201318. https:\/\/doi.org\/10.1038\/s41581-021-00418-2.","journal-title":"Nat Rev Nephrol"},{"key":"823_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(24)02385-7","volume":"405","author":"M Ostermann","year":"2025","unstructured":"Ostermann M, Lumlertgul N, Jeong R, See E, Joannidis M, James M. Acute kidney injury. Lancet. 2025;405:241\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(24)02385-7.","journal-title":"Lancet"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0885066620911601","volume":"36","author":"MS Heavner","year":"2021","unstructured":"Heavner MS, McCurdy MT, Mazzeffi MA, Galvagno SM Jr, Tanaka KA, Chow JH. Angiotensin II and vasopressin for vasodilatory shock: a critical appraisal of catecholamine-sparing strategies. J Intensive Care Med. 2021;36:635\u201345. https:\/\/doi.org\/10.1177\/0885066620911601.","journal-title":"J Intensive Care Med"},{"key":"823_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-022-01021-9","volume":"12","author":"MA Ammar","year":"2022","unstructured":"Ammar MA, Ammar AA, Wieruszewski PM, Bissell BD, Long MT, Albert L, et al. Timing of vasoactive agents and corticosteroid initiation in septic shock. Ann Intensive Care. 2022;12:47. https:\/\/doi.org\/10.1186\/s13613-022-01021-9.","journal-title":"Ann Intensive Care"},{"key":"823_CR25","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/ejhf.1987","volume":"22","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, et al. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020;22:2056\u201364. https:\/\/doi.org\/10.1002\/ejhf.1987.","journal-title":"Eur J Heart Fail"},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"GMC Rosano","year":"2018","unstructured":"Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4:180\u20138. https:\/\/doi.org\/10.1093\/ehjcvp\/pvy015.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"823_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2215\/CJN.09340817","volume":"13","author":"BF Palmer","year":"2018","unstructured":"Palmer BF, Clegg DJ. Hyperkalemia across the continuum of kidney function. Clin J Am Soc Nephrol. 2018;13:155\u20137. https:\/\/doi.org\/10.2215\/CJN.09340817.","journal-title":"Clin J Am Soc Nephrol"},{"key":"823_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026426","volume":"11","author":"E Uijl","year":"2022","unstructured":"Uijl E, Ye D, Ren L, Mirabito Colafella KM, van Veghel R, Garrelds IM, et al. Conventional vasopressor and vasopressor-sparing strategies to counteract the blood pressure-lowering effect of small interfering RNA targeting angiotensinogen. J Am Heart Assoc. 2022;11:e026426. https:\/\/doi.org\/10.1161\/JAHA.122.026426.","journal-title":"J Am Heart Assoc"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00823-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00823-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00823-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:21:12Z","timestamp":1786976472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00823-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":29,"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00823-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lucas Maciel de Almeida Corr\u00eaa, Gabriel Rian Mazur, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa, Ivan Felipe Dutra J\u00fanior, Gabriel Costa de Santana, Luiggi Kevin Virgino Brand\u00e3o, Yan Roberth Delmiro Silva, and Let\u00edcia Esteves Dante declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}